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Mesenchymal stem cells (MSCs) represent a heterogeneous population of stromal cells with pluripotent mesenchymal
diﬀerentiation potential. They have been found to have immunosuppressive properties and the ability to modulate angiogenesis
and endogenous tissue repair by in vitro and animal studies. Clinical trials have examined the utility of these cells in autoimmune
and inﬂammatory conditions. In particular, in allogeneic hematopoietic stem cell transplant (HSCT), multiple studies have been
conducted to explore the use of MSC to treat acute and chronic graft-versus-host disease (GVHD) and for cotransplantation with
HSCT to promote HSC engraftment and prevent GVHD. We review here the results of these studies and discuss some challenges
of this treatment modality in this disease setting.
1.Introduction
Mesenchymal stem cell and multipotent mesenchymal stro-
malcellsarebothdesignatedMSCnomenclaturebythelatest
consensus statement from the International Society for Cel-
lular Therapy (ISCT) [1]. This is a group of heterogeneous
plastic-adherent cells that can be isolated from bone marrow
(BM), adipose tissue, placenta, cord blood, and other tissues.
The name MSC simply implies the mesenchymal origin of
these cells and is not necessarily the limit of their diﬀeren-
tiation potential. Given the heterogeneity of the stromal cell
compartment and the limited number of these cells that have
true stem-cell-like properties, consistent characterizations of
MSC were proposed to maximize intersample equivalency in
data comparison [2]. Three criteria are now commonly used
among researchers:
(1) adherence to plastic in in vitro culture,
(2) surface antigen expression positivity (95%) for CD
105, CD73, CD90 and negativity (2%) for lineage
markers including CD45, CD34, CD14 or 11b, CD79
alpha or CD19, and HLA-DR,
(3) capacity for diﬀerentiation in vitro into osteoblasts,
adipocytes, and chrondroblasts.
In vitro MSC have been shown to exert immunosuppres-
sive eﬀects via direct suppression of T and B lymphocytes,
NK cell, and dendritic cell functions [3–12]. They can also
secrete cytokines important for angiogenesis, tissue repair,
and immune modulation such as VEGF, IL-6, IL11, M-
CSF, and stem cell factor [13–15]. In animal models, some
r e p o r t ss u g g e s tp r o l o n g e ds u r v i v a lo fs k i na n ds o l i do r g a n
grafts with MSC infusion [4, 16–18] while protection from
graft-versus-host disease (GVHD) by MSC in the mouse
m o d e li sl e s sc l e a r[ 19–21]. This is partially attributed to the
complex biology of these cells compounded by variations in
activation of their potential functions by diﬀerent culture
t e c h n i q u e sa c r o s sd i ﬀerent labs. Interspecies diﬀerences in
MSCfunctionsanddiscrepanciesbetweeninvitroandinvivo
studies have also been described [22].
In recent decade, there has been intense interest in clin-
ical applications of MSC for modulation of immunity
and endogenous repair. At the time of writing, there are
currently 179 clinical trials using MSC registered at clinical-
trials.gov. Crohn’s disease, cardiac ischemia, limb ischemia,2 Advances in Hematology
amyotrophiclateralsclerosis,diabetes,multiplesclerosis,and
liver cirrhosis are just a few of the conditions listed. Graft-
versus-host disease (GVHD) was one of the ﬁrst conditions
to be studied.
Acute graft-versus-host disease (aGVHD) is a major
causeofmorbidityandmortalityafterallogeneichematopoi-
etic stem cell transplant or donor lymphocyte infusion.
This can occur in up to 30–50% of patients despite HLA-
matched sibling transplant and even more frequently in
HLA-mismatched unrelated donor transplants (60–80%)
[23]. Corticosteroids remain the ﬁrst-line treatment; how-
ever,despite the addition of othersteroid sparing agentssuch
as calcineurin inhibitors, prognosis for steroid-refractory
aGVHD patients remains poor with 5-year survival of less
than 30%. Furthermore, many patients may either progress
from aGVHD or develop de novo chronic GVHD (cGVHD)
with similar high risk of morbidity and mortality [23]. MSC
has been examined for use both in the prevention and
treatment of acute and chronic GVHD. We review here the
clinical trials of MSC in the prevention and treatment of
GVHD and discuss some of the challenges that remain to be
addressed.
2. MSC in the Treatment of
Graft-versus-HostDisease
2.1. MSC Harvested from Bone Marrow Aspirate for IV
Infusion. The ﬁrst case of MSC infusion for treatment
of GVHD was described by Le Blanc et al. in 2004
[24]. A nine-year-old boy with acute lymphoblastic leukemia
received a matched unrelated donor peripheral blood stem
cell transplant after his third remission. He developed rash
on day 11, diarrhea on day 22, and liver enzyme elevation
on day 25 after transplant. He did not respond to corti-
costeroids, extracorporeal photochemotherapy, inﬂiximab,
daclizumab, mycophenolate mofetil, and methotrexate. By
day 70, aGVHD had progressed to grade IV severity, and
on day 73, he received an IV infusion of 2 × 106 cells/kg of
MSC from his mother. No adverse events were noted with
the infusion, and it was reported that symptoms began to
improve within 5 days and resolved within two weeks. The
patient developed recurrent GVHD at day 150, shortly after
his immunosuppression was discontinued to treat minimal
recurrent disease. He received another infusion of MSC
from his mother at half of the ﬁrst dose. He was reported
to have a complete response of his GVHD and remission
of ALL. He subsequently died 19 months after transplant
from recurrence of gut GVHD and respiratory failure from
pneumonia [25].
This patient was also included in a pilot study reported
by Ringden et al. [25] of eight patients with steroid-
resistant grade III to IV aGVHD and one patient with
chronicGVHDwhoweretreatedwithMSCbetweenOctober
2001 and March 2005. Two patients were children, and
seven were adults. MSC was cultured from bone marrow
aspirates of healthy donors and used fresh from culture at or
under four passages. Flow cytometry analysis for phenotype
was performed prior to release. Six patients received one
infusion, and three patients received two infusions. The
median MSC dose was 1 × 106 cells/kg (range 0.7–9). Of
the twelve infusions, two were from HLA-identical donors,
six from haploidentical donors, and four from mismatched
unrelated donors. Two patients who received two MSC
infusionshaddiﬀerentdonorsforeachinfusion.Themedian
time between transplant and MSC infusion was 108 days
(range 32–283 days) and between onset of GVHD symptoms
and infusion was 37 days (range 7–90 days). There were
no adverse events reported from the MSC infusions, and
six of the eight aGVHD patients had complete response.
The patient with chronic GVHD was reported to have a
transient liver response without any skin response. Median
response time was not reported. In addition to the pediatric
patient previously described in Le Blanc et al. ’04, one of
the remaining two patients who received two infusions did
not have signiﬁcant response to the ﬁrst infusion of 0.7 ×
106 cells/kgbutwasreportedtohavehadacompleteresponse
with second infusion of 2 × 106 cells/kg. The third patient
who received two infusions also had an escalation of dosage
from 0.7 to 1.3 × 106 cells/kg. He did not respond to either
infusion and died eight days later from multiorgan failure.
No patient developed chronic GVHD.
In autopsy of two nonresponders, HLA-speciﬁc DNA
from MSC donor was found in the GI lymph nodes of the
nonresponder who died eight days after infusion, but not
identiﬁed in another nonresponder who died three weeks
after MSC infusion. In another patient who had a complete
response to MSC infusion who died 19 months later from
recurrence of GVHD, MSC donor DNA was not found at
autopsy [25].
Sixteen patients who had grade II–IV GVHD of the gut
during the same time period served as a control. Compared
to these patients, those who received MSC infusion had
almost three-time longer survival (P = 0.03) [25]; however
it appeared that there was an initial intention to treat these
patients with MSC, and they did not receive therapy due
to factors such as limited laboratory resources, patient
refusal, progressive primary malignancy, and improvement
in GVHD.
This report was followed shortly by a report from Muller
et al. [26] of MSC infusion in seven pediatric patients
between June 2004 and July 2005. Five of the seven patients
receivedMSCtotreatGVHD.TwopatientshadacuteGVHD,
and three had chronic GVHD. Two chronic GVHD patients
received two MSC infusions. Two patients who received stem
celltransplantfrommatchedunrelateddonorsreceivedMSC
from haploidentical family donors. The remaining three
patients received MSC from their same HSC donors: one
matchedsiblingdonorandtwohaploidenticalfamilydonors.
The median time from transplant to infusion was 250 days
(range 80–768 days). The median time between onset of
symptoms and infusion was not reported. The median dose
was 2.5 × 106 cells/kg (0.4–3 × 106). MSCs cultured for less
than 6 weeks were used fresh from culture without frozen
storage. The variation in dosage was largely due to technical
limitation of the interdonor variation in growth kinetics. No
adverse events were reported with MSC infusions; however
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and well two years after MSC infusion and three years after
transplant at the time of report. The other patient with
aGVHD died of relapsed AML with no change in GVHD
status. One patient with cGVHD had a slight improvement
and remained alive 2.5 years after ﬁrst MSC infusion and
four years after transplant. A second patient with cGVHD
died of cGVHD 1 year after MSC infusion, three years from
transplant. The third patient with cGVHD did not respond
and died from EBV-associated lymphoproliferative disorder
18 months after MSC infusion, 27 months after transplant.
aGVHD response did not appear to be dose dependent as
one response occurredafter a single dose of 0.4 × 106 cells/kg
while others did not respond to two to three doses of 2 ×
106 cells/kg. In addition phenotype purity information was
not available on two patients and low at 83% for one patient.
The signiﬁcance of lower purity is unclear as patients who
received high-purity MSC did not necessarily respond better.
Additionally, in this report, a nine-year-old boy with
MDS who had received a second hematopoietic stem cell
(HSC) transplant from a haploidentical donor was trans-
fusedwith2 ×106 cells/kgofMSCfromthesameHSCdonor
atday17afterhissecondtransplanttopreventgraftrejection
which was successful, and he remained alive and well three
years later. Another patient, a fourteen-year-old girl with T-
cell ALL received MSC from the same haploidentical HSC
donor for hemophagocytosis. She received three doses of
0.4 × 106 cells/kg nine months after transplant. She had
partial response with improvement in her platelet count
and decreased degree of hemophagocytosis on bone marrow
biopsy. She then went on to receive a second HSC transplant
which engrafted well, and she was disease free two years later.
These preliminary reports were followed by the largest
study published to date, a multicenter, phase II study of
bone marrow-derived MSC for treatment of steroid-resistant
aGVHD from the European Group for Blood and Bone Mar-
row Transplantation Mesenchymal Stem Cell Consortium
[27]. Fifty-ﬁve patients were treated between October 2001
andJanuary2007.Twentyﬁve-patientswerechildrenwithan
overall median age of 22 years (range 0.5–64yrs). A majority
had grade III (n = 25) or IV (n = 25) GVHD. Nine patients
had GVHD involvement of three organs, and twenty-six
patients had involvement of two organs.
The median time from transplant to MSC infusion was
103 days (range 27–533 days) using HLA-identical (n = 5),
haploidentical (n = 18), and HLA-mismatched unrelated
(n = 69) donors. Most patients in the study received one
(n = 27) or two infusions (n = 22) with a median dose per
infusion of 1.4 × 106 (range 0.4–9 × 106) cells/kg. MSC were
harvested from culture at 4 passages or less and frozen until
use. Of the patients who received more than one infusion,
sevenpatients(6children,1adult)receivedasecondinfusion
for GVHD prevention when immunosuppressive drug was
reduced. Five patients had a complete response initially
and received subsequent doses with GVHD recurrence.
Seventeen patients without sustained complete response and
ﬁve patients with partial responses received repeat doses. Of
those,12patientsdidnotresponddespitemultipleinfusions.
The overall response rate was 71% (39/55, CR 30, PR 9)
with a median time to complete response after infusion of
18 (range 3–63) days. The response rate after one dose was
52.7% (27 CR and 2 PR, n = 55). A majority (n = 24)
of these responders received MSC from HLA-mismatched
unrelated donors. There was no diﬀerence in the MSC dose
between responders and nonresponders. One patient who
did not respond to a ﬁrst dose of 0.6 × 106 cells/kg did
respond to a second dose of 2 × 106 cells/kg. The overall
response rate was slightly higher in the pediatric population
(pediatric: 84%, 21/25; adults: 60%, 18/30; P = 0.07).
Howeverthestudywasinadequatelypoweredtodemonstrate
statistical signiﬁcance between the two populations. There
was no statistically signiﬁcant correlation between response
to MSC infusion and type or severity of GVHD, treatments
prior to MSC infusion, age or HLA-matching of MSC
donors, or time between onset of GVHD symptoms and
MSC infusion. It was noted that variable responses were seen
when cells expanded from one donor were given to several
recipients.
Transplantation-related mortality was signiﬁcantly lower
in complete responders compared to partial and nonre-
sponders (100 days: CR 13% versus non-CR 60%, P =
0.002; 1 year: CR 37% versus non-CR 72%, P = 0.002).
With a median followup of 16 months (1.5–64 months),
the overall estimated 2-year survival for the patients in
this study was 35% (95% CI 22–38%) and was signiﬁ-
cantly better in complete responders (52%, 95% CI 34–
70%) versus noncomplete responders (16%, 95% CI 0–
32%, P = 0.018). There was also a suggestion of better
trend for 2-year estimated survival in pediatric population
compared to adults, although the study was inadequately
powered to address this. Nine of the MSC responders
died from infections. Of the 21 survivors, eight patients
developed chronic GVHD, with four having extensive or
severe involvement. Three patients had recurrence of their
hematologicmalignancies(onemultiplemyeloma,oneacute
lymphoblastic leukemia, one acute myeloid leukemia). One
pediatric patient with Pearson’s disease developed acute
myeloid leukemia de novo from endogenous hematopoietic
cells. One patient developed Epstein-Barr virus-associated
posttransplant lymphoproliferative disorder.
This landmark study was the ﬁrst large-sample, prospec-
tive, multicentered study with a longer median followup
that suggested that MSC therapy may be eﬀective in treating
GVHD. The use of diﬀerent types of MSC donors suggested
that clinical responses could be achieved with third party
unmatched MSC raising the possibility of storage for imme-
diate access.
2.2. Clinical Trials Exploring Other Methods of MSC Culture
and Deliveries. Arima et al. [28] reported a limited series
of three adult patients who were treated with intra-arterial
infusion of MSC for localized treatment of liver and gut
GVHD between April 2006 and May 2008. These patients
were steroid refractory with either a calcineurin inhibitor
or mycophenolate mofetil. Fresh MSCs harvested from
bone marrow aspirates of their respective HSC donors
were cultured in donor serum up to three weeks and
then infused into superior mesenteric, gastroduodenal, and
inferior mesenteric arteries for gut GVHD and common4 Advances in Hematology
hepatic artery for hepatic GVHD via selective angiography.
No immediate adverse events were associated with the MSC
infusions. The dose of MSC was signiﬁcantly limited by the
rate of culture expansion and was signiﬁcantly less than
other studies (median 0.51 × 106 cells/kg/treatment, range
0.32–2.0 × 106 cells/kg/treatment, in fractions of 0.08–0.50
× 106 cells/kg/arterial distribution). Unfortunately, no major
response was observed. One patient had overall stability
of GVHD and died of respiratory failure from idiopathic
pneumonia 103 days after MSC infusion (199 days after
transplant). A second patient had a transient improvement
in gut GVHD two weeks after MSC infusion as proven by
biopsy. He had recurrence of GVHD ﬁve weeks later and
died from intestinal obstruction and hepatic failure 58 days
after MSC infusion, day 178 from transplant. The third
patient had progressive GVHD and died from respiratory
failure 20 days after MSC infusion, day 178 from transplant.
On autopsy, she was found to have hepatic GVHD, diﬀuse
alveolar damage of the lung without evidence of GVHD
involvement or infection, and severe CMV and EBV colitis
which interfered with accurate assessment of GI GVHD
i n v o l v e m e n t .T h es t u d yw a ss t o p p e dd u et ol a c ko fG V H D
response. At least in this study, donor serum did not appear
to improve the culture yield of MSC and added to the
complexity of the manufacturing process. Subsequent study
using platelet lysate reported below may be a more accessible
method of manufacturing. Although this study was limited
to three patients, it did not appear that direct injection of
MSC to site of GVHD involvement improved the treatment
response, leading to the larger question of homing pattern
and mechanisms of actions of MSC in vivo.A ta n yra t e ,gi v e n
the added risk of invasive angiography without additional
beneﬁt, this method was not pursued further. Finally the
ﬁndings of idiopathic pneumonia and severe viral enteritis
raise the concern of MSC-exacerbating risk and severity of
infection in this already immunocompromised population.
Zhou et al. [29] reported four adult patients with
chronic sclerodermatous GVHD who received MSC between
September 2006 to August 2008. The MSC infusions were
given directly into the bone marrow via anterosuperior
iliac spine. The MSCs used were up to 6 passages in cul-
ture, one of the highest reported in the literature. The
immunophenotype was slightly diﬀerent from others (no
CD73). Multilineage diﬀerentiation was conﬁrmed in cul-
ture. The MSC infusion was limited to 1-2 × 107 cells per
infusion, which would be signiﬁcantly less than the average
1-2 × 106 cells/kg in the other studies. The patients did
receive4to8repeatedinfusions,whichisthehighestnumber
of repeat infusions examined. Again, no immediate adverse
events were observed with MSC infusions. All four patients
were reported to have had signiﬁcant improvement in their
RodnanSkinscore(>70%improvement)andimprovedjoint
mobility. One patient had signiﬁcant tapering of GVHD
medications. With a median followup of 14.1 (4.6–23)
months, all patients were alive. None had recurrent primary
hematologic malignancies. In addition, correlative studies
showed that in all four patients, there was a consistent trend
in all patients with an increased ratio of Th1 to Th2 cell ratio
as treatment continued. Although the dosage of MSC was
less than that used in previous aGVHD study, the smaller
doses with multiple infusions appears to have promise in
cGVHD raising the question of frequency and timing rather
than just dose as a factor in response. Whether intra-BM
infusion truly bypasses lung sequestration and improves
eﬃcacybyincreasingMSCintheaﬀected microenvironment
requires further study. This method of infusion is certainly
more cumbersome and less desirable if IV infusion is equally
eﬃcacious.
In followup of the Arima et al. study that used human
serum to culture bone-marrow-derived MSC, Perez-Simon
et al. [30] reported a series of 18 adult patients treated with
MSC cultured with human serum. In feasibility assessment
of the manufacturing, 28 MSC expansions were attempted.
78.5% (22/28) of the cultures achieved the goal of >1 ×
106 cells/kg with a median of 26 days of culture. Notably, in
eight cultures, platelet lysate was also added to improve the
growth of MSC. In only one instance was MSC treatment
not given due to inability of full expansion of MSC despite
adding platelet lysate. Of the eighteen patients treated
between February 2007 and December 2009, 10 patients
had aGVHD, 8 had cGVHD. Patients received 0.2–2.9 ×
106 c e l l s / k gp e rd o s eu pt of o u rd o s e s .I na G V H D ,ﬁ v e
patients received one dose, one patient each received 2 and
3 doses, and three patients received four doses. None of
the patients who received more than one dose had a better
quality of response. One patient had CR, 6 had PR, and 3 did
not respond. At the time of publication (last FU median FU
not given), only one patient was alive. Among the nine who
have died, two died from GVHD, ﬁve from infection, one
from relapsed disease, and one from venoocclusive disease.
In cGVHD, four patients received one dose of MSC, three
received two doses, and one patient received three doses.
One patient had CR, 3 PR, and 4 did not respond. The
patientwhohadCRalsohadseverethrombocytopeniawhich
resolved after MSC infusion. This data combined with 4 pts
in Zhou et al. support additional study of this modality in
adult cGVHD setting.
Given the concern for possible prion disease with fetal
bovine serum, von Bonin et al. [31] also reported the use of
MSC expanded in media containing human platelet lysate
for the treatment of steroid-refractory aGVHD in their
compassionate use program. Bone marrow aspirates from
12 healthy donors were expanded for one or two passages
with media containing 10% platelet lysate derived from
single-donor platelet apheresis concentrate. The MSC were
examined by ﬂow cytometry for phenotype, their osteogenic
and adipogenic diﬀerentiation capacity were tested by stan-
dard diﬀerentiation culture, and their immunosuppressive
capacity was tested via suppression of CD4+ T cell prolifera-
tion by thymidine incorporation assay. The MSCs were not
HLA matched to aGVHD patients. Thirteen patients were
recruited between March and December of 2007. All patients
had failed steroid plus another immunosuppressive agent.
The median time from transplant to ﬁrst MSC infusion was
41days(range20–91)andfromonsetofaGVHDwas16days
(range 4–31). The median number of MSC infusions was
2 (range 1–5). The median interval between infusions was
7 days (range 3–19). The median dose given each time wasAdvances in Hematology 5
0.9 × 106 cells/kg (range 0.6–1.1 × 106 cells/kg). There were
no adverse events with infusions. At 28 days after infusion,
there were one CR, one PR, and ﬁve MR. For each of the
aﬀected organs, the response rates were 3/6 CR and 0/6 PR
for skin, 2/10 CR and 3/10 PR for liver, and 2/11 CR and
2/11 PR for GI. At the time of report, 9 patients have died:
four within 28 days after MSC infusion and four during
the two years of followup. Four were alive with a median
followup of 257 days (range 185–692) from transplant. The
authors reported that the 1- and 2-year survivals of patients
with similar grades of steroid-refractory GVHD at their
institution who did not receive MSC were 28% (11/40) and
20% (8/40), respectively. While no formal statistical analysis
was performed, the survival appears to be comparable. The
small number of patients in this report makes assessment
diﬃcultregardingintersamplevariabilitybetweenMSCfrom
diﬀerentdonors,aswellasfreshversusfrozenMSCandMSC
functional capacity variation with diﬀerent platelet lysate.
Nevertheless platelet lysate may be a more readily available
human blood product for MSC culture.
Fang et al. [32] had the only report of adipose-derived
MSC in the treatment for steroid-refractory aGVHD. Six
patients were recruited between September 2002 and August
2005. Adipose-derived MSCs were harvested from abdomi-
nal adipose tissue of donors undergoing lipectomy surgery.
Cells were assessed for phenotype by ﬂow cytometry prior
to release. The median time of ﬁrst MSC infusion from
transplant was 71 days (range 65–243) and from onset of
GVHD was 38.5 days (range 7–58). MSC dose was 1 ×
106 cells/kg. Overall, ﬁve of the six patients had complete
response(83.3%).Oneoftheﬁverespondersdied13months
later from relapsed AML. The remaining four were alive
and well at the time of report, with median survival after
transplant of 26.5 months (range 18–90 months). One
patient who had GVHD of skin, liver, and GI had partial
response with ﬁrst infusion. She had progressive symptoms
47 days later and received another MSC infusion with
complete response. The patient who did not respond to MSC
infusion had skin and GI GVHD. She died 16 days after
MSC infusion from multiorgan failure after systemic fungal
infection and hemorrhagic cystitis. Larger sample study is
warranted to assess the eﬃcacy of this more readily available
source of MSC for this clinical application.
2.3. Commercially Manufactured MSC (Prochymal). In the
largest, prospective, open-labeled multicentered phase II
study conducted in the US, Kebriaei et al. [33]r a n d o m i z e d
adult patients with de novo aGVHD to IV MSC infusions at
either 2 × 106 or 8 × 106 cells/kg along with corticosteroid.
Thirty one patients were treated among 16 centers between
April 2005 and June 2006. The MSC, Prochymal, was
manufacturedbyOsirisTherapeuticsInc.frombonemarrow
aspirates of 6 healthy donors, cultured in fetal bovine
serum, and frozen until IV infusion. Lot-to-lot consistency
was ensured by immunophenotyping via ﬂow cytometry
(per International Society for Cellular Therapy position
statement), documented cell viability, functional testing by
TNFR1 expression quantiﬁcation on MSC, and qualitative
assay measuring the inhibition of IL2Ralpha expression on
activated T cells by MSC. Sixteen patients received low-dose
MSC, and ﬁfteen patients received high dose. Each patient
received MSC from one donor. Because of improved MSC
availabilitywithpremanufacturing,allpatientsreceivedtheir
ﬁrst MSC infusion within 48 hours from diagnosis of grade
II–IV GVHD and a second infusion 3 days later. Of note,
more than half of the patients had grade II GVHD which
was lower severity than the Le Blanc ’08 study (10/15 high-
dose group and 11 of 16 low-dose group). No adverse events
were seen with MSC infusions. No ectopic tissue formation
was seen with radiologic imaging. Initial response rate was
high, with 24 CR (10 in high-dose group, 14 in low-dose
group)and5PR(highdosegroup).19patientswhoachieved
CR did not require second-line treatment in 90 days. Time
to response was also rapid with 42% patients achieving CR
at day 7, 52% by day 14, and 77% at day 28. CR was not
correlated to donor source, GVHD location, or grade. 22/31
patients survived to 90 days. Patients who achieved CR had
signiﬁcantly improved survival than non-CR patients (CR:
21/24, 88%; non-CR: 1/7, 14%; P = 0.0008). Three patients
who had achieved CR died from infections (pneumonia,
meningitis, aspergillus enteritis). Median time to death for
the nine patients was 44 days from MSC infusion (13–63
days). Those in non-PR died from progressive GVHD (3),
relapsed malignancy (1), and CNS bleed (1). In terms of
risk of primary malignancy relapse, three patients relapsed
in a two-year follow-up period. Twelve grade 3 infections
and three grade 4 infections, per CTC version 3, were seen.
This is the ﬁrst large prospective study of MSC therapy
in de novo aGVHD. It also conﬁrmed the feasibility of
commercial manufacturing, allowing some uniformity in
release criteria and more immediate accessibility. The good
clinical response may be due to both early initiation of MSC
therapy from onset of aGVHD and a higher proportion
of patients with lower-grade severity. Results suggest better
response in patients with lower GI GVHD. This may be
consistent with autopsy ﬁnding from previous study of MSC
homing to GI lymph node within days after infusion [25].
Prasad et al. [34]r e p o r t e dt h eu s eo fP r o c h y m a li np e -
diatric patients with grade III/IV refractory aGVHD. Twelve
patients were treated between July 2005 and June 2007.
The median number of therapies other than steroid was 3
(range 2–5). MSCs premanufactured from four healthy adult
donors were used. The dosing schedule was twice weekly
infusion at least 3 days apart for weeks (induction phase).
For patients who had partial response or mixed response
at 32 days evaluation, weekly infusion at the same cell dose
was given for 4 more weeks (maintenance phase). Those
who had achieved complete response or no response at 32
days evaluation did not receive additional infusions. The
ﬁrst two patients were treated with a higher dose of 8 ×
106 cells/kg before protocol amendment to reduce the dose
to 2 × 106 cells/kg for the remaining 10 patients on the study.
The protocol was amended due to ﬁnding of equivalent
eﬃcacy with both doses from Kebriaei et al. The median
duration between transplant and MSC therapy was 98 days
(45–237) and between aGVHD diagnosis and MSC therapy
was 46 days (18–157). The median number of infusions
per patient was 8 (2–21). By the end of induction phase,6 Advances in Hematology
two patients achieved CR, and 6 had PR. By the end of all
treatments, 7 patients (58%) had CR, two PR (17%). Two
patients who achieved CR had recurrence of grade IV skin
and gut GVHD, respectively. They were retreated with MSC
infusion with signiﬁcant PR, with symptom improvement to
grade I. All 12 patients had gut GVHD. The CR response
rate to gut involvement was 75% (9/12). Survival at 100 days
was 58% (7/12). Five of 12 (42%) patients were alive after a
median followup of 611 days (427–1111). The estimated 2-
year survival for patients treated with MSC was 40% (95%
CI: 20–82%) and for patients achieving CR was 68% (95%
CI:40–100%).ThemediantimetodeathfromMSCinfusion
was 58 days (36–185 days, n = 7). Two patients with
CR died from sepsis (stenotrophomonas and pseudomonas
aeruginosa). Five non-CR patients died from infections (n =
3, fungal n = 2, CMV encephalitis n = 1), EBV-associated
lymphoproliferativedisorder(n = 1),andmultiorgansystem
failure (n = 1).
Osiris Therapeutics Inc. had two phase III trials investi-
gating their product Prochymal in ﬁrst-line treatment and
in steroid-refractory aGVHD across transplant centers in
United States, Canada, and Australia. The trial in ﬁrst-line
aGVHD was a double-blinded, placebo-controlled trial that
enrolled 192 patients. Primary endpoint was the proportion
ofpatientssurvivingatleast90dayswithacompleteresponse
in steroid alone versus those who received steroid along
with Prochymal. Treatment failure was deﬁned as failure
to achieve complete response in 28 days, need to increase
steroiddose,oradditionofotherimmunosuppressiveagents.
Accrual for both studies is complete. No peer-reviewed
publication of trial results is available yet. The last company
released news report in 2009 did not show a statistically
signiﬁcant diﬀerence (Prochymal 45% versus placebo 46%,
n = 192, http://www.osiristx.com/).
In the steroid-refractory population, the primary end-
point in this phase III, double-blind, placebo-controlled
study was durable complete response for at least 28 days.
Patients were randomized at 2:1 ratio for either Prochymal
or placebo. This trial enrolled 260 patients. In the company’s
public news release in 2009, the preliminary analysis has
not shown a statistical diﬀerence between Prochymal and
placebo on primary endpoint in this population (Prochymal
35% versus placebo 30%, n = 260). However subpopulation
analysis did show an improved response rate in liver GVHD
(Prochymal76%versusplacebo47%,P = 0.026,n = 61)and
GI GVHD (Prochymal 88% versus placebo 64%, P = 0.018,
n = 71). Patients with liver GVHD also had signiﬁcant
durable complete response with Prochymal (Prochymal 25%
versus placebo 5%, P = 0.046). The company reasoned that
the lack of statistical signiﬁcance in the overall population
may be related to the higher response rate already achievable
with standard of care in the skin GVHD patients, which is a
signiﬁcant proportion of the accrued patients.
In addition, consistent with previous literature reports,
the combined pediatric cohort from both studies showed
strong trend in improvement of response rate (Prochymal
86% versus placebo 57%, P = 0.094, n = 28). Based on this
subgroup analysis, Osiris ﬁled an amendment with the FDA
to broaden the entry criteria to include patients with severe
GVHD of the liver. In addition FDA has granted expand-
ed access, making Prochymal available to children with
GVHD.
2.4. Summary. In summary, clinical data to date support
the safety of MSC to treat acute and chronic GVHD
(summarized in Tables 1 and 2). Multiple early phase studies
have explored the feasibility of diﬀerent methods of MSC
manufacturing and delivery. While phase II studies suggest
clinical eﬃcacy of this modality, two large, multicenter,
prospective phase III trials have examined the use of MSC
to treat de novo aGVHD and therapy-refractory acute and
chronic GVHD without evidence of eﬃcacy as determined
by the primary endpoints. Better understanding of the
mechanism of action of this cell therapy modality is needed
to optimize therapy and identify the GVHD population that
may beneﬁt from this treatment.
The largest clinical experience has been with IV infusion
of MSC cultured from bone marrow-aspirate in fetal bovine
serum. Some important factors have helped ease the tran-
sition to commercialize the manufacturing process of this
treatment modality. First, the ﬁnding of comparable eﬃcacy
andlackoftoxicityinMSCfromHLA-mismatchedunrelated
donors allows the use of premanufactured, cryopreserved
MSC from a larger donor source, thereby removing the
time constraint and increasing the accessibility of MSC.
Second, commercially available, quality-controlled culture
media and supplement can help minimize some of the
intersample variability in the culture process. To further
improve accessibility and reduce cost, the utility of other
more readily available sources of MSC such as adipose
tissue warrants further study. In addition, platelet lysate
may be another viable alternative for culture supplement to
improvegrowthkineticswhilereducingconcernforzoonosis
as a concern with animal serum. The current phenotype
criteria to characterize MSC in general does not identify
phenotypevariationwithinthisheterogeneouspopulationof
cells that may make a batch of MSC from one donor more
eﬀective from another. Identiﬁcation of such phenotype
could improve the eﬃciency of this technology.
The concern for increased risk of disease relapse and
infection due to the immunosuppressive properties of MSC
cannot be adequately addressed with the existing data.
Heterogeneous patient populations were enrolled across
these studies with limited controls for comparison. Many
enrolled patients are at inherently at high risk for disease
recurrence and infection due to the nature of their disease
and treatment. This is a valid concern that will need to be
carefully analyzed in randomized, placebo-controlled phase
III studies.
The dose and frequency of MSC infusion to maximize
clinical eﬃcacy has not been addressed in these smaller
studies. While the technical limitations from manufacturing
have improved to allow for infusion in the range of
106 cells/kg, the biokinetics of the infused MSC is poorly
understood. The most commonly used dose has been 1-2 ×
106 cells/kg. Limited observations suggest that higher dose is
not more eﬀective. While some patients did not respond toAdvances in Hematology 7
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lowerdoses,therearereportsofthosewhomayevenrespond
to a single dose as low as 0.4 × 106 cells/kg. In addition,
the average time to response after infusion appears to be
b e t w e e n1t o3w e e k s[ 27, 29]. While some patients who
respond to ﬁrst treatment will continue to respond at GVHD
relapse, there are those who do not respond to repeated
infusion if they did not have response to ﬁrst infusion.
Relevant to ﬁnding the optimal dose and frequency is better
understanding of MSC traﬃcking and homing pattern in
patients and their mechanism of action in the treatment
of GVHD. Donor MSC has not been identiﬁed in patients
from bone marrow aspirate cultures irrespective of clinical
response, suggesting a lack of donor MSC engraftment. Do-
nor MSC has been found on autopsy in area of tissue
inﬂammation such as GI lymph node within days after
infusion, but not seen weeks after infusion. The question
remains to be addressed whether MSC residence is necessary
for its proposed biologic functions. One possibility is that
MSC may diﬀerentiate into a progeny cell population in
the body. Labeling MSC to better track its homing pattern
and its fate after homing can address this possibility [35].
MSC also may alter homeostatic microenvironment through
its interaction with immune and hematopoietic cells. This
eﬀect may persist beyond time of MSC residence in the tis-
sue. Parekkadan and Milwid [36] explored using chemical
engineering modeling principles to develop dosing regimen
based on this kinetic information.
Data also raise the possibility that subpopulations of
patients such as those with speciﬁc organ involvement may
be more likely to respond to MSC treatment. In the era
of personalized medicine, we need more precise methods
to identify patients who will likely beneﬁt from this labor-
intensive and costly treatment. Clinically relevant prognostic
tests and biomarkers that identify those patients who will
likely respond to MSC infusion and to assist in decisions in
treatment dose and schedule would be very useful but are
currently poorly deﬁned. The correlation between changes
in ratio of Th1/Th2 cells and clinical response in Zhou et al.
study [29] suggest the possibility that such biomarkers may
be discoverable. Bioinformatics approaches can be used to
tease out the intricacies of this complex patient population
to identify distinctive proﬁles of GVHD patients who may
beneﬁt from this treatment modality.
3. MSC in the Prevention of
Graft-versus-HostDisease
Insomeanimalmodels, MSCinfusionimprovedthesurvival
ofskinandsolidorgangrafts[4,16,19,21].Somepatientsin
previously described studies who were at risk of graft failure
or rejection had good response with MSC infusion [26]. This
prompted a number of investigators to examine the use of
MSC cotransplant with HSCT to promote engraftment and
prevent GVHD.
3.1. MSC Cotransplant in HLA-Identical HSCT. Lee et al.
[37] from Korea ﬁrst reported cotransplantation of allo-
geneicMSCwithHSCinanattempttoimproveengraftment.
A twenty-year-old woman with high-risk acute myelogenous
leukemia (M1 with complex chromosomal abnormalities)
received peripheral blood mobilized, T-cell depleted HSC
from her haploidentical father. Antithymocyte globulin
(15mg/kg/d) was given as part of her conditioning regimen
on day −6t o−3. Five weeks prior to scheduled HSC
transplant, MSC was cultured from bone marrow aspirate
of her father and harvested after four passages for fresh
infusion. She received 1.5 × 106 cells/kg of MSC one hour
after the second HSC infusion on day 2 of transplant (total
5.7 × 106 HSC infused over two days). No additional
prophylactic immunosuppressive treatment was given after
transplant. She received G-CSF from day 4 to 14. Her ANC
was above 0.5 × 109 cells/L on day 12, and her platelet
was above 20 × 109/L without transfusion support by day
15. Bone marrow and peripheral blood mononuclear cell
evaluation at day 18 showed 20–30% cellularity in the bone
marrow and trilineage engraftment and complete donor
chimerism by PCR. On day 42, she had an episode of CMV
pneumonia that was successfully treated with ganciclovir
and IV immunoglobulin. She maintained engraftment for
up to 31 months at the time of report, did not develop
acute or chronic GVHD, and remained well without signs
of AML relapse. Interestingly, culture of her bone marrow-
derived MSC at six and 12 months after transplant showed
host genotype despite maintenance of donor genotype in
hematopoetic mononuclear cells.
With this encouraging report, a number of investigators
haveexaminedtheroleofMSCincotransplantation.Lazarus
et al. [38] reported a phase I study across seven centers in the
U.S. and Italy. Fifty-six adult patients were enrolled between
December 1999 and March 2001. MSCs were cultured from
bone marrow aspirate of their respective HLA-identical HSC
sibling donors. All samples were transported to production
center at Osiris Therapeutics, Inc in Baltimore, Md. MSCs
were cultured with fetal bovine serum and cryopreserved
until use. The planned MSC dosage was 1, 2.5, and 5 ×
106 cells/kg, with 18 patients per dosage group. Only MSC
cultures from ﬁve donors were able to achieve the highest
dosage. Treatment arms were adjusted to the two lower
dosages for subsequent patients. MSC culture was feasible
in 91% of cases (51/56). The median time to achieve the
intended dosage was comparable for the diﬀerent dosages,
30 days (range 21–48 days). A total of 46 patients were
treated with MSC infusions (1 × 106 cells/kg n = 20, 2.5
× 106 cells/kg n = 21, 5 × 106 cells/kg n = 5) followed
by HSC infusion four hours later (BM HSC n = 19, PB
HSC n = 27). All patients received GVHD prophylaxis
with IV cyclosporine (3mg/kg/d) starting at day 1 that was
adjusted to oral doses as deemed clinically appropriate with
discontinuation by 6 months after transplant. Methotrexate
w a sa l s og i v e nI Vo nd a y s1 ,3 ,a n d6( 1 0m g / m 2). Day 11
methotrexate was eliminated due to concern for potential
toxicity to infused MSC. While all patients experienced at
least one adverse event as expected associated with HSCT
during the peritransplant period, no immediate toxicity was
noted with MSC infusion, and no ectopic tissue formation
was noted on radiologic imaging as part of routine clinical
care. Recombinant hematopoietic growth factor supportAdvances in Hematology 11
was not routinely given. The median time to engraftment
appeared to be comparable across dosage groups: median
time to ANC > 0.5 × 109/L 14 days (11–26), ANC > 1 ×
109/L 15 days (12–24), platelet > 20 × 109/L 20.5 days (15–
36), and platelet > 50 × 106/L 21 days (15–36). The ANC
engraftment was slower for those who received BM HSC
which is consistent with general population of patients who
receive BM versus PB HSC. Twenty-three patients (50%)
experienced aGVHD, with 5 (11%) patients having grade III
severity, and 2 (4%) at grade IV. Of the thirty-six patients
who were evaluable past 90 days after transplant, twenty-two
patients (61%) developed cGVHD (limited 14, extensive 8).
The incidence was higher in patients who received BM HSC
versus PB HSC. Twelve patients had relapse or progression of
their primary hematologic malignancy with a median time
of 214 days following transplant (14–688). The estimated
2-year progression free survival and overall survival for
the 46 treated patients were 53% (95% CI: 37–66%) and
78% (95% CI: 63–87%), respectively. The causes of deaths
were infection (2), relapse (2), hemorrhage (2), hepatic
venoocclusive disease (1), GVHD (1), cardiac (1), and GI (1)
dysfunction. At a median time of 8 months (n = 18) and
sixteen months (n = 7) following transplant, patients under-
went bone marrow aspirate evaluation for MSC chimerism.
Only two patients were found to have persistent donor
chimerism in their cultured MSC at less than 14%. The
overallconclusionfromthisstudyisthatcotransplantationis
technically feasible (>90% manufacturing success) and safe.
Balletal.[39]alsoreportedatthattimeaphaseI/IIstudy
of 14 children treated with MSC cotransplant along with
haploidentical HSC from relatives. MSC culture and HSC
collection were successful in all donors. MSCs at less than
3 passages were used either fresh or after cryopreservation.
Mean MSC dose was 1.6 × 106 (1–3.3 × 106) cells/kg. No
toxicity was seen with MSC infusion. Compared to the 47
historical controls from the two participating institutions,
the 14 patients who received cotransplant had a faster
engraftment: leukocyte > 1 × 109/L, median 11.5 days
(range 9–15 days) for study patients versus 14.9 days (10–
26) for controls, P = 0.009; reticulocyte > 20 × 109/L, 12
(10–31) days versus 23 (9–41) days, P = 0.03. Although
ANC and platelet recovery trend was also earlier by a few
days, this did not reach statistical signiﬁcance. The faster
rate of leukocyte engraftment was attributed to lymphocyte
recovery. These patients also had sustained engraftment (0%
failure versus 15% in controls, P = 0.14) and no increased
risk of infection. Two (14%) patients developed aGVHD of
grade I-II severity, and one (7%) patient developed limited
involvement cGVHD. This was lower than historical control
although statistical signiﬁcance was not reached. Chimerism
analysis of bone marrow-derived MSC from recipient at 3
months interval up to one year did not identify signiﬁcant
donor chimerism. Only three patients had a transient donor
MSC engraftment at less than 2% at 3 months. Four patients
died (28%) compared to 11 (40.7%) in the control group.
The estimated relapse rate and overall survival were not
comparable between the two groups due to diﬀerence in
followup. Among the study patients, two died from relapsed
disease and two from infection. With a median followup of
9 (2–28) months, the estimated relapse rate was 18%, and
overall survival was 72%.
Ning et al. [40] reported their single-center experience in
China with the highest rate of adverse events. In this open-
label trial for patients undergoing HLA-identical sibling BM,
PB, or both HSC, patients were randomized to receive either
HSC per standard transplant protocol or HSC cotransplant
with MSC from the same HSC donor. Thirty patients were
enrolled between March 2003 and March 2004. There was
one 17-year-old patient in the MSC cotransplant group
and one 16-year-old patient in the control group. The
remainder of the patients were all adults. Characteristics
of the primary hematologic malignancy were comparable
between the groups. Conditioning regimen was equivalent
between the groups. Cyclosporin and methotrexate (day 1,
3, 6) were used for GVHD prophylaxis. The planned dose
of MSC for infusion was 1-2 × 106 cells/kg in 30 days.
This was achieved in only two patients. Therefore the MSC
infusion dose was reduced, and ﬁve enrolled patients were
still excluded from the protocol due to inability to meet
MSC production criteria. The feasibility of manufacturing
in this study was 66.7% (10/15). The median MSC dose
infusedwas0.34 ×106 cells/kg(0.03–1.53 ×106 cells/kg).No
immediate toxicities were observed with MSC infusion. The
engraftment time was not statistically signiﬁcantly diﬀerent
between the two groups. One patient who received 0.34 ×
106 cells/kg of MSC in cotransplant did not engraft and died
19 days after transplant. With MSC cotransplant, both the
incidence and severity of GVHD were decreased compared
to the control group. Four of nine (44.4%) patients in MSC
group had aGVHD, while 11/15 (73.3%) patients in the
control group had aGVHD. Only 1 (11%) patient in MSC
group had grade II aGVHD while 8 (53.3%) did in the
control group. One (of seven, 14.3%) patient in the MSC
grouphadlimitedcGVHDwhilefour(of14,28.6%)patients
in the control group had cGVHD, 1 limited, and 3 extensive.
The rate of infection was comparable between the two
groups, four of 10 in MSC and 5 of 15 in control. However,
the MSC cotransplant group had signiﬁcantly higher rate
of disease relapse at an earlier time than the control group
(MSC: 6/10, 60%, median time 63 days, range 39–1062 days;
control: 3/15, 20%, median time 177 days, range 66–450
days; P = 0.02). With a median followup of 36.6 months
(0.6–44 months), six patients in the MSC group and ﬁve
in the control group have died. The three-year disease-free
survival was 30.0% for MSC and 66.7% for control group
(P = 0.035). The three-year overall survival was 40.0%
for MSC and 66.7% for control group. Rate of GVHD and
relapse did not correlate with MSC dose. The investigators
closed the study earlier than the planned 25 patients per arm
due to this observation of increased disease relapse.
Zhang et al. [41] reported the results of MSC cotrans-
plantation with HLA-identical sibling PBSCT in a single
center in China. Fourteen patients were enrolled between
February 2002 and September 2005. Two months prior to
transplant, MSC was cultured from the bone marrow aspi-
rate of the same HSC donor. Commercially available culture
mediasupplement(HumanMSCsStimulatorySupplements,
StemCell Technologies) was used. MSC were cryopreserved12 Advances in Hematology
until transplant. Two (14.2%) of the fourteen cultures were
unsuccessful. Culture time for the remainder of the samples
was 36.8 ± 4.5 days. Twelve patients subsequently underwent
cotransplantation. MSC were infused 1 hour after HSC
(1.78 ± 0.35 × 106 cells/kg). Cyclosporine and methotrexate
(15mg/m2 on day 1, 10mg/m2 on day 3, 6, 11) were used for
GVHD prevention. Median time to granulocyte engraftment
(>0.5 × 109/L) was 11 days (7–15), platelet engraftment
(>20 × 109/L) was 13.5 (10–17) days. All patients had 100%
donor chimerism in their peripheral blood mononuclear
cells 1 month after transplant. Three patients did not
develop aGVHD. Seven had grade I aGVHD. Three of
these patients progressed to cGVHD, two limited, and one
extensive. Two patients developed grade II-III aGVHD, one
of whom progressed to extensive cGVHD. The two patients
with extensive cGVHD were treated with cyclosporine and
steroid. One responded to treatment, and the second patient
died from infection. Four patients had CMV infections,
all responded to ganciclovir and IV immunoglobulin. Four
(33.3%) patients had disease relapse. They received DLI, and
only one patient responded. The ﬁve deaths were due to
relapse (3) and infections (2, pneumonia and liver failure
from hepatitis B). The remaining seven patients were alive
29–57 months after transplant at the time of report.
3.2. MSC Cotransplant in Other Types of HSCT. Le Blanc
et al. [42] reported a small pilot study in Europe where
seven patients (3 adults and 4 pediatric) received MSC
cotransplant with HSC. This was a second transplant for
three patients in the study, two for graft failure, and one
for graft rejection. The HSC sources were PBSC (4), BM
(2) and cord blood (1). HSC donors were matched sibling
(3),matchedunrelateddonor(2),andmismatchedunrelated
donors (2). MSC donors were the same as HSC donors
for the matched sibling and haploidentical donors for those
whose HSC donors were unrelated. All MSCs were cultured
from bone marrow aspirates of adults in fetal bovine serum.
All patients received 1 × 106 cells/kg of MSC within 4 hours
of HSC infusions. Six patients received thymoglobulin prior
to HSCT. One patient developed anaphylaxis to thymoglob-
ulin and received Campath instead. For GVHD prophylaxis
peritransplant, three patients received methotrexate and
cyclosporine, two received cyclosporine alone, one with
prednisolone and cyclosporine, and one with tacrolimus and
sirolimus. Hematopoietic growth factor support was not
given. Median engraftment time for ANC > 0.5 × 106/L
was 12 (10–28) days, for platelet > 50 × 106/L was 15
(11–45) days. This was on average about a week shorter
than the institutional average at that time. In addition,
transfusion requirement was low before engraftment, par-
ticularly for adults (RBC median 2 (0–6) units, platelet 1
(1–3) units). All three patients who received retransplant
due to graft failure or rejection had successful engraftment.
No immediate adverse event was seen with MSC infusion,
nor was ectopic tissue formation noted. One patient was
alive and well 15 months after transplant without GVHD.
Four patients developed grade I GVHD, and two patients
developed grade II GVHD. These mild GVHD responded
to treatment with steroid. Only one patient with grade
II GVHD progressed to chronic GVHD of the skin and
gut. His symptoms were managed with tacrolimus and
steroid, and he was alive and well 28 months following
transplant. One patient died from aspergillosis 8 months
after transplant. All other patients were alive and well with
a median followup of 23.5 (10–37) months after transplant.
One patient had serious multibacterial infection within
the ﬁrst month following transplant and one patient had
recurrent, serious infections, including Listeria meningitis
eight months after transplant. One patient developed VOD
and two had mild-to-moderate hemorrhagic cystitis. Even
though majority (6/7) of the patients in this study developed
GVHD, they were milder, adequately managed, and did not
lead to signiﬁcant morbidity or any mortality. In addition,
MSC therapy appeared to be eﬀective in retransplantation
with prior history of graft rejection/failure.
Gonzalo-Daganzo et al. [43]r e p o r t e das m a l ls t u d y
that was also stopped early, examining the use of MSC
cotransplantation in patients who receive single-unit cord
blood and T-cell depleted mobilized PBSC in enhancing
engraftment and preventing GVHD. In this phase I/II study,
nine adults were treated with MSC cotransplant, and 46
patients treated at the same time in the institution served
as control. Baseline patient characteristics were comparable
between the two groups. MSC were cultured from bone
marrow aspirate of HSC donors 4–6 weeks prior to CB
transplant. MSCs were harvested and cryopreserved with
a median culture time of 28 days (16–34) and 2 passages
(1–3). All CB, PBSC, and MSC were infused within 24
hours. The median dose of MSC was 1.2 (1.04–2.22) ×
106 cells/kg. No immediate toxicities were seen with MSC
infusion. Cyclosporine and methylprednisolone (1mg/kg,
day 1 to 10–14) were used for GVHD prophylaxis. G-CSF
was given on day 1 until ANC was greater than 1 × 109/L.
No signiﬁcant diﬀerence was seen in ANC and platelet
engraftment or time to 100% CB chimerism. Chimerism
analysis at day 15, 35, 100, and one year after transplant for
seven patients did not show any donor chimerism. In the
MSC group, one (11.1%) patient developed grade I aGVHD,
4 (44.4%) with grade II, and none had grade III-IV. In
contrast, 18 (39%) patients in the control group had grade
I aGVHD, 5 (11%) had grade II, and 6 (13%) had grade III-
IV aGVHD. Among the 4 patients who had grade II aGVHD
in the MSC cotransplant group, two did not respond to
steroid therapy. These two patients received one and three
infusions of MSC and achieved CR. One patient in the MSC
group died at day 30 with multiorgan system failure without
aGVHD. The remaining patients were alive with median
followup of 8 months (3.5–22). There was one (11.1%)
diseaserelapseintheMSCgroupandsix(13%)inthecontrol
group. Two-year cumulative incidence of transplant-related
mortality was 0.11 (95% CI: 0.02–0.71) for MSC group and
0.37 (95% CI: 0.25–0.54). While the trend in decreased TRM
andincreasedOSisinterestingly,thestudywasstoppedearly,
and the sample size was too small to assess for statistical
signiﬁcance. The investigators reasoned that the dual single-
unit CB and PBSC transplant morbidity and mortality were
better than they had predicted. Therefore MSC cotransplant
in this setting may not be cost-eﬀective. In addition theirAdvances in Hematology 13
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observation of eﬀectiveness of MSC infusion at the time of
steroid-refractoryaGVHDalongwithothersreportedshifted
their practice to design studies investigating the role of MSC
infusion in treatment rather than prophylaxis of GVHD in
this type of dual transplant.
Themost recentpublication byBaronetal.[44]r epo rt ed
cotransplantation of MSC in the higher risk population of
patients receiving HSC from HLA-mismatched unrelated
donor with nonmyeloablative conditioning regimen. Twenty
adult patients enrolled between January 2007 and September
2008receivedcotransplantwithHSCfromHLA-mismatched
unrelated donor and MSC from third-party unrelated
donors. Sixteen patients with similar baseline characteristics
who received similar HSC transplant between May 2002 and
August 2006 served as control. MSCs were harvested from
bone marrow aspirate and cultured for 2 passages, then
cryopreserved until use. MSC cotransplant patients received
conditioning regimen with Flu (30mg/m2,d a y s−4, −3,
−2) and TBI (2 Gy, day 0). MSCs were infused between
30–120 minutes before HSC infusion. GVHD prophylaxis
included mycophenolate mofetil (15mg/kg po TID, day
0–42) and tacrolimus (titrated to keep blood levels 15–
20ng/mLthroughday28and10–15ng/mLthereafter,poday
−3t ob et a p e r e do ﬀ by one year if no symptoms of GVHD).
Theengraftmenttimewasnotsigniﬁcantlydiﬀerentbetween
the two groups. The proportion of patients who developed
severe aGVHD were lower with MSC cotransplantation,
although this did not reach statistical signiﬁcance (grade
II–IV: 45% versus 56%; grade IV: n = 2, 10% versus
n = 3, 19%). However the one-year probability of dying
from GVHD or infection while on treatment for GVHD
was signiﬁcantly lower with MSC cotransplant (10% versus
31%, P = 0.02). In addition the 100-day (5%) and 1-
year nonrelapse mortality were signiﬁcantly lower with
MSC cotransplant (1 year: 10% versus 37% in control
group, P = 0.02). The one year overall survival was
signiﬁcantly improved with MSC cotransplant (80% versus
44%, P = 0.02). In multivariate analysis, MSC cotransplant
was strongly associated with reduced NRM (HR = 0.2, 95%
CI: 0.04–0.9, P = 0.03) and overall mortality (HR = 0.4, 95%
CI: 0.1–0.9, P = 0.03). In contrast to the Ning et al. report
earlier, these investigators did not ﬁnd decreased GVT eﬀect
as evidenced by equivalent 1-year cumulative incidence of
diseaserelapseandequivalentdiseaseCRrateaftertransplant
inpatientswhohadresidualdiseaseatthetimeoftransplant.
Consistent with prior studies, the incidence of grade IV
aGVHD was lower with MSC cotransplant. This is the ﬁrst
study to conﬁrm survival advantage of MSC cotransplant by
multivariate analysis. A large, multicenter study is underway
in Belgium to determine if these ﬁndings will be conﬁrmed.
3.3. Summary. Similar to MSC therapy for treatment of
GVHD, MSC cotransplant with HSCT appears to be safe
with minimal infusion-associated toxicities across multiple
studies (summarized in Table 3). Preliminary studies do
not suggest dramatic improvement in the rate of HSC
engraftment with cotransplantation. However there may be
a trend for less blood product transfusion support during
engraftment period. GVHD occurrence may be decreased
and less severe with cotransplantation, translating to better
morbidity and survival advantage. The risk of disease relapse
andinfectionhasbeenmorecontroversialinthecotransplant
settingwithonereportofincreasedrisksinboththatreached
statistical signiﬁcance [40] and a more recently published
negative trial [44]. Both the clinical eﬃcacy and potential
risks will need to be conﬁrmed in larger sample phase III
studies.
Perhaps even more relevant in the cotransplant setting
is the understanding of potential interactions between MSC
and immunosuppressive medications. Preclinical studies
suggest detrimental eﬀect of tacrolimus and rapamycin on
MSC functions [45, 46]. However in an animal model of
heart transplant, MSC combined with mycophenolate or
rapamycin appears to have synergistic immunosuppressive
eﬀect [16]. More preclinical data is needed to inform
better designof combined pharmacotherapyand celltherapy
approach.
Given the consideration for risk of GVHD and cost and
logistics of MSC cotransplant, it appears worth further
exploration to determine whether high-risk patients receiv-
ing mismatched transplant and those with a history of graft
rejection/failure may beneﬁt from cotransplantation. Similar
challenges exist with MSC therapy in cotransplant as with
treatment of GVHD: no donor MSC engraftment was seen
and mechanism of action is not clear.
4. Conclusions
In conclusion, clinical evidence suggests that MSC may have
some activity in the treatment and prevention of GVHD;
however the largest randomized trials have not conﬁrmed
thistodate.Abetterunderstandingoftheunderlyingbiology
isneededtorationallydesignfurtherphaseIIItrialsattempt-
ing to conﬁrm eﬃcacy and clarify risk of disease relapse
and infection. Optimization of MSC therapy in GVHD and
other clinical conditions will require better understanding of
these cells’ mechanism of action and how these functions
are aﬀected by other existing treatment modalities. This
knowledge can then be translated to improve the design of
MSC therapy. Advances in personalized medicine should be
employed to identify the patient population likely to beneﬁt
from MSC therapy and the role of MSC in combination with
existing treatment modalities.
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